Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11855MR)

This product GTTS-WQ11855MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11855MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6808MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ506MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ14547MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ9646MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ7207MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ5246MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ14225MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ4309MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW